Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, F.
  • Arenas, E. J.
  • Aguilar, H.
  • Serra-Musach, J.
  • Ruiz de Garibay, G.
  • Boni, J.
  • Maicas, M.
  • Du, S.
  • Lorio, F.
  • Herranz-Ors, C.
  • Islam, A.
  • Prado, X.
  • Llorente, A.
  • Petit, A.
  • Vidal, A.
  • Catalá, I.
  • Soler, T.
  • Venturas, G.
  • Rojo-Sebastian, A.
  • Serra, H.
  • Cuadras, D.
  • Blanco, I.
  • Lozano, J.
  • Canals, F.
  • Sieuwerts, A. M.
  • Weerd, V. de
  • Look, M. P.
  • Puertas, S.
  • García, N.
  • Perkins, A. S.
  • Bonifaci, N.
  • Skowron, M.
  • Gómez-Baldó, L.
  • Hernández, V.
  • Martínez-Aranda, A.
  • Martínez-Iniesta, M.
  • Serrat, X.
  • Cerón, Julián
  • Brunet, J.
  • Barretina, M. P.
  • Gil, M.
  • Falo, C.
  • Fernández, A.
  • Morilla, I.
  • Pernas, S.
  • Plà, M. J.
  • Andreu, X.
  • Seguí, M. A.
  • Ballester, R.
  • Castellà, E.
  • Nellist. M.
  • Morales, S.
  • Valls, J.
  • Velasco, A.
  • Matias-Guiu, X.
  • Figueras, A.
  • Sánchez-Mut, José Vicente
  • Sánchez-Céspedes, M.
  • Cordero, A.
  • Gómez-Miragaya, J.
  • Palomero, L.
  • Gómez, A.
  • Gajewski, T. F.
  • Cohen, E. E. W.
  • Jesiotr, M.
  • Bodnar, L.
  • Quintela-Fandino, M.
  • López-Bigas, N.
  • Valdés-Mas, R.
  • Puente, X. S.
  • Viñals, F.
  • Casanovas, O.
  • Graupera, M.
  • Hernández-Losa, L.
  • Ramón y Cajal, S.
  • García-Alonso, L.
  • Sáez-Rodríguez, J.
  • Esteller, M.
  • Sierra, A.
  • Martín-Martín, N.
  • Matheu, A.
  • Carracedo, A.
  • González-Suárez, E.
  • Nanjundan, M.
  • Cortés, J.
  • Lázaro, C.
  • Odero, M. D.
  • Martens, J. W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, M. H.
  • Villanueva, A.
  • Gomis, R. R.
  • Pujana, M. A.
13 páginas, 7 figuras, Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure., This study was supported by the following bodies and grants: the Scientific Foundation ‘Asociación Española Contra el Cáncer’ (AECC, Stable Coordinated Group, Hereditary Cancer); the BBVA Foundation; the Eugenio Rodríguez Pascual Foundation grant 2012; Generalitat de Catalunya AGAUR SGR 2012 grants 283, 290 and 312, and SGR 2014 grants 364, 530, and 535; Spanish Ministry of Health ISCIII FIS grants PI10/00057, PI10/00222, PI10/01422, PI12/01528, PI13/00132, and PI14/00336. ISCIII RTICC grants RD06/0020/1051, RD12/0036/0007, RD12/0036/0008 and RD12/0036/0063; Spanish Ministry of Science and Innovation, ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’, MINECO grants SAF2010- 20203 and SAF2013-46196; and the Telemaraton 2014 ‘Todos Somos Raros, Todos Somos Únicos’ grant P35. EJA was supported by ‘la Caixa’ PhD fellowship program, F Iorio was supported by a fellowship from the EMBL-EBI and the Wellcome Trust Sanger Institute Postdoctoral (ESPOD) program, and NL-B, ME and RRG were supported by ICREA., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

  • Robles, Eloy F.
  • Mena-Varas, Maria
  • Barrio, Laura
  • Merino-Cortes, Sara V.
  • Balogh, Péter
  • Du, Ming-Qing
  • Akasaka, Takashi
  • Parker, Anton
  • Roa, Sergio
  • Panizo, Carlos
  • Martin-Guerrero, Idoia
  • Siebert, Reiner
  • Segura, Victor
  • Agirre, Xabier|||0000-0002-6558-9560
  • Macri-Pellizeri, Laura
  • Aldaz, Beatriz
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Zhang, Shaowei
  • Moody, Sarah
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Tousseyn, Thomas
  • Broccardo, Cyril
  • Brousset, Pierre
  • Campos-Sanchez, Elena
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Sánchez García, Isidro
  • Fernandez-Luna, Jose Luis
  • Garcia-Muñoz, Ricardo
  • Pena, Esther
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • González, Marcos
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Climent Bataller, Joan|||0000-0002-8927-6614
  • Ferrandez, Antonio
  • Sagaert, Xavier
  • Melnick, Ari M.
  • Prosper, Felipe|||0000-0001-6115-8790
  • Oscier, David G.
  • Carrasco, Yolanda R.
  • Dyer, Martin J. S.
  • Martinez-Climent, Jose A.
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2 - 3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3 -deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas. The homeobox NKX2 family of transcriptional factors has been shown to regulate fundamental developmental processes. Here, the authors show that NKX2-3 is a bona fide oncogenic driver in marginal-zone B-cell lymphoma and that it promotes lymphomagenesis by shaping lymphocyte dynamics and promoting BCR signalling.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

  • Mateo, Francesca|||0000-0002-2342-7010
  • Arenas, Enrique J.|||0000-0001-7076-2666
  • Aguilar, Helena
  • Serra-Musach, Jordi
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Boni, Jacopo|||0000-0003-2626-9393
  • Maicas, Miren|||0000-0003-1404-5552
  • Du, Shisuo
  • Iorio, Francesco|||0000-0001-7063-8913
  • Herranz-Ors, Carmen|||0000-0002-2866-0321
  • Islam, Abul
  • Prado, X.
  • Llorente, Alicia
  • Petit Montserrat, Anna|||0000-0002-9284-095X
  • Vidal, August|||0000-0001-5727-2099
  • Català, Isabel
  • Soler, Teresa
  • Venturas, G.
  • Rojo-Sebastian, Alejandro|||0000-0001-6439-3518
  • Serra, Helena
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Blanco Guillermo, Ignacio|||0000-0002-7414-7481
  • Lozano, José
  • Canals, Francesc|||0000-0002-0650-1135
  • Sieuwerts, Anieta M.
  • De Weerd, Vanja
  • Look, Maxime P.
  • Puertas, Sara
  • García, Nadia
  • Perkins, Archibald S.
  • Bonifaci, Núria|||0000-0002-8193-6825
  • Skowron, Margaretha A.
  • Gómez-Baldó, Laia
  • Hernández, Vanessa
  • Martínez-Aranda, Antonio
  • Martínez-Iniesta, Maria|||0000-0001-6252-6671
  • Serrat Farran, Xènia|||0000-0001-7611-5400
  • Cerón, Julián|||0000-0003-4739-2243
  • Brunet, Joan|||0000-0003-1945-3512
  • Barretina-Ginesta, Maria-Pilar|||0000-0003-0074-6614
  • Gil, Mercedes|||0000-0002-7387-2139
  • Falo, Catalina|||0000-0002-5714-6823
  • Fernández, Adela
  • Morilla, Idoia
  • Pernas, Sonia|||0000-0002-1485-5080
  • Plà, Maria Jesus
  • Andreu, Xavier
  • Seguí Palmer, Miguel Ángel|||0000-0002-5103-6746
  • Ballester, Rosa|||0000-0002-7870-4185
  • Castellà Fernández, Eva
  • Nellist, Mark D.
  • Morales, Saleta
  • Valls, Joan|||0000-0002-4806-7568
  • Velasco Sánchez, Ana
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Figueras, Agnes
  • Sánchez-Mut, José Vicente|||0000-0002-9292-8521
  • Sánchez Céspedes, Montse|||0000-0002-6045-5627
  • Cordero Casanovas, Alex|||0000-0002-2224-7122
  • Gómez-Miragaya, Jorge|||0000-0003-1801-4681
  • Palomero, Luis|||0000-0002-9144-1017
  • Gomez-Caamaño, Antonio|||0000-0002-9773-4590
  • Gajewski, Thomas F.
  • Cohen, Ezra E. W.
  • Jesiotr, Marzena
  • Bodnar, Lubomir
  • Quintela-Fandino, Miguel|||0000-0003-1648-1964
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Valdés-Mas, Rafael
  • Puente, Xose S.|||0000-0001-9525-1483
  • Viñals, Francesc|||0000-0002-9918-6751
  • Casanovas, Oriol|||0000-0002-4298-3995
  • Graupera, Mariona|||0000-0003-4608-4185
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Garcia-Alonso, Luz|||0000-0002-7863-9619
  • Saez-Rodriguez, J.
  • Esteller, M.|||0000-0003-4490-6093
  • Sierra-Jimenez, Angels|||0000-0003-1023-3492
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Matheu Fernandez, Ander
  • Carracedo, Arkaitz|||0000-0001-5957-1260
  • González-Suárez, Eva|||0000-0003-0858-8171
  • Nanjundan, Meera
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Odero, Maria D.|||0000-0002-8858-2054
  • Martens, John W. M.
  • Moreno-Bueno, Gema
  • Barcellos-Hoff, Mary Helen
  • Villanueva, Alejandro|||0000-0001-5164-0006
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Pujana, Miguel Angel|||0000-0003-3222-4044
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells

  • Maicas, Miren
  • Vázquez Urio, Iria
  • Alis, Rafael
  • Marcotegui, Nerea
  • Urquiza, Leire
  • Cortés-Lavaud, Xabier
  • Cristóbal, Ion
  • García-Sánchez, María A.
  • Odero, María D.
Acceso cerrado a este documento. No se encuentra disponible para la consulta pública. Depositado en Academica-e para cumplir con los requisitos de evaluación y acreditación académica del autor/a (sexenios, acreditaciones, etc.)., Transcriptional activation of the EVI1 oncogene (3q26) leads to aggressive forms of human acute myeloid leukemia (AML). However, the mechanism of EVI1-mediated leukemogenesis has not been fully elucidated. Previously, by characterizing the EVI1 promoter, we have shown that RUNX1 and ELK1 directly regulate EVI1 transcription. Intriguingly, bioinformatic analysis of the EVI1 promoter region identified the presence of several EVI1 potential binding sites. Thus, we hypothesized that EVI1 could bind to these sites regulating its own transcription. In this study, we show that there is a functional interaction between EVI1 and its promoter, and that the different EVI1 isoforms (EVI1-145 kDa, EVI1-Δ324 and MDS1-EVI1) regulate the transcription of EVI1 transcripts through distinct promoter regions. Moreover, we determine that the EVI1-145 kDa isoform activates EVI1 transcription, whereas EVI1-Δ324 and MDS1-EVI1 act as repressors. Finally, we demonstrate that these EVI1 isoforms are involved in cell transformation; functional experiments show that EVI1-145 kDa prolongs the maintenance of hematopoietic stem and progenitor cells; conversely, MDS1-EVI1 repressed hematopoietic stem and progenitor colony replating capacity. We demonstrate for the first time that EVI1 acts as a regulator of its own expression, highlighting the complex regulation of EVI1, and open new directions to better understand the mechanisms of EVI1 overexpressing leukemias., We thank Dr. Wieser (Medizinische Universitaet Wien) for the plasmid pEFzeo-MDS1EVI1, and Isabel Moreno-Miralles for technical support and useful discussion. This work was supported by Ministerio Educación y Ciencia (AP2007-03879); Ministerio de Economía y Competitividad (PI14/02073), integrado en el Plan Estatal de I+D+I 2013–2016 y cofinanciado por el ISCIII-Subdirección General de Evaluación y Fomento de la investigación y el Fondo Europeo de Desarrollo Regional (FEDER); Departamento de Salud del Gobierno de Navarra (29/2015); and ISCIII-RTICC (RD12/0036/0063).